New Alzheimer's Study Tests Preventative Drug Combinations

Researchers are launching a four-year study to see if drug combinations can stop Alzheimer’s before it begins.

Updated on Oct. 21, 2026 in Alzheimer’s

A close-up view of a clear petri dish containing translucent neural cell cultures in gel on a sterile laboratory surface. — Mass General Brigham has received $66 million in funding to study whether drug combinations can prevent Alzheimer's disease in at-risk individuals. AI Illustration. Upload story photo >

Live Poll

Should medical research funding prioritize preventative treatments for age-related diseases like Alzheimer's?

Mass General Brigham has secured $66 million in funding to advance a four-year study testing drug combinations for Alzheimer's prevention. This research aims to address a disease currently affecting over 7 million Americans.

Why it matters

Researchers are pivoting toward preventative strategies by testing drug combinations that target the buildup of harmful amyloid proteins. This funding allows for a robust look at whether these interventions can stop the disease from progressing in at-risk individuals.

A new four-year study will evaluate five to 10 drug combinations in 300 patients who have tested positive for Alzheimer's biomarkers. It remains unknown which specific substances will be prioritized for these combination therapies.

The players

Rudolph Tanzi

Head of the Henry and Allison McCance Center for Brain Health who has studied Alzheimer's genetics for decades.

Mass General Brigham

A Boston-based integrated health care system and academic medical center.

Acta Pharmaceuticals

A Boston-based biotechnology company currently conducting an experimental clinical trial.

Advanced Research Projects Agency for Health

A federal agency that funds high-risk, high-reward health research to accelerate medical breakthroughs.

The details

The research utilizes a model known as 'Alzheimer's in a Dish,' which incorporates human brain cells and gel to screen potential drug substances before they move to human trials. By targeting the early buildup of amyloid proteins, investigators hope to determine if specific drug pairings can slow or prevent the onset of Alzheimer's pathology in asymptomatic individuals at risk for the disease.

1980: Rudolph Tanzi begins his career at Massachusetts General Hospital.
2014: The research team develops the Alzheimer's in a Dish screening model.
2023: Biogen and Eisai gain approval for their Alzheimer's medication, Leqembi.
October 15, 2026: Acta Pharmaceuticals announces $24 million in seed financing.
October 21, 2026: Mass General Brigham announces $66 million in new research funding.

Health Landscape

This project represents a shift from current monoclonal antibody treatments like Leqembi toward combination therapies aimed at prevention. It builds upon the historical progression of Alzheimer's care from late-stage symptomatic management to early biological intervention.

This research is focused on preventative strategies for those with known biomarkers, which is a topic to raise during consultations with a neurologist. While this study is ongoing, those with a family history of the disease should discuss the latest screening options with their physician.

The takeaway

The move toward combination therapies signals a new era in potentially preventing Alzheimer's before symptoms emerge. If you have concerns about cognitive health or family history, discuss the relevance of current biomarker testing with a neurologist.